Sequential immunological analysis of HBV/HCV co-infected patients during Peg-IFN/RBV therapy

被引:6
|
作者
Kondo, Yasuteru [1 ]
Ueno, Yoshiyuki [1 ]
Ninomiya, Masashi [1 ]
Tamai, Keiichi [1 ]
Tanaka, Yasuhito [2 ]
Inoue, Jun [1 ]
Kakazu, Eiji [1 ]
Kobayashi, Koju
Kimura, Osamu [1 ]
Miura, Masahito [3 ]
Yamamoto, Takeshi [4 ]
Kobayashi, Tomoo [5 ]
Igarashi, Takehiko [6 ]
Shimosegawa, Tooru [1 ]
机构
[1] Tohoku Univ, Grad Sch Med, Div Gastroenterol, Aoba Ku, Sendai, Miyagi 980, Japan
[2] Nagoya City Univ, Sch Med, Virol & Liver Unit, Nagoya, Aichi 467, Japan
[3] S Miyagi Med Ctr, Dept Gastroenterol, Oogawara, Miyagi, Japan
[4] Tohoku Kosei Nenkin Hosp, Dept Gastroenterol, Sendai, Miyagi, Japan
[5] Tohoku Rosai Hosp, Dept Hepatol, Sendai, Miyagi, Japan
[6] Osaki Citizen Hosp, Dept Gastroenterol, Osaki, Japan
关键词
Dual infection; HBV; HCV; Immunopathogenesis; HEPATITIS-B-VIRUS; REGULATORY T-CELLS; HEPATOCELLULAR-CARCINOMA; COINFECTED PATIENTS; DUAL INFECTION; GENOTYPE-B; VIRAL INTERACTIONS; IMMUNE-RESPONSES; INTERFERON; RIBAVIRIN;
D O I
10.1007/s00535-012-0596-x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The immunopathogenesis of dual chronic infection with hepatitis B virus and hepatitis C virus (HBV/HCV) remains unclear. The in vivo suppressive effects of each virus on the other have been reported. In this study we aimed to analyze the virological and immunological parameters of HBV/HCV coinfected patients during pegylated interferon/ribavirin (Peg-IFN/RBV) therapy. One patient with high HBV-DNA and high HCV-RNA titers (HBV-high/HCV-high) and 5 patients with low HBV-DNA and high HCV-RNA titers (HBV-low/HCV-high) were enrolled. Twenty patients monoinfected with HBV and 10 patients monoinfected with HCV were enrolled as control subjects.. In vitro cultures of Huh 7 cells with HBV/HCV dual infection were used to analyze the direct interaction of HBV/HCV. Direct interaction of HBV clones and HCV could not be detected in the Huh-7 cells. In the HBV-high/HCV-high-patient, the HCV-RNA level gradually declined and HBV-DNA gradually increased during Peg-IFN/RBV therapy. Activated CD4- and CD8-positive T cells were increased at 1 month of Peg-IFN/RBV-therapy, but HBV-specific IFN-gamma-secreting cells were not increased and HBV-specific interleukin (IL)-10 secreting cells were increased. The level of HBV- and HCV-specific IFN-gamma-secreting cells in the HBV-high/HCV-high-patient was low in comparison to that in the HBV- or HCV-monoinfected patients. In the HBV-low/HCV-high-patient, HCV-RNA and HBV-DNA rapidly declined during Peg-IFN/RBV therapy. Activated CD4- and CD8-positive T cells were increased, and HBV- and HCV-specific IFN-gamma-secreting cells were also increased during Peg-IFN/RBV-therapy. The immunological responses of the HBV-high/HCV-high patient were low in comparison to the responses in HBV and HCV monoinfected patients. Moreover, the response of immune cells in the HBV-high/HCV-high patient during Peg-IFN/RBV therapy was insufficient to suppress HBV and HCV.
引用
收藏
页码:1323 / 1335
页数:13
相关论文
共 50 条
  • [1] Sequential immunological analysis of HBV/HCV co-infected patients during Peg-IFN/RBV therapy
    Yasuteru Kondo
    Yoshiyuki Ueno
    Masashi Ninomiya
    Keiichi Tamai
    Yasuhito Tanaka
    Jun Inoue
    Eiji Kakazu
    Koju Kobayashi
    Osamu Kimura
    Masahito Miura
    Takeshi Yamamoto
    Tomoo Kobayashi
    Takehiko Igarashi
    Tooru Shimosegawa
    Journal of Gastroenterology, 2012, 47 : 1323 - 1335
  • [2] Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV
    A. Rivero-Juarez
    J. A. Mira
    A. Camacho
    K. Neukam
    I. Perez-Camacho
    A. Caruz
    J. Macias
    J. Torre-Cisneros
    J. A. Pineda
    A. Rivero
    Infection, 2013, 41 : 21 - 26
  • [3] Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV
    Rivero-Juarez, A.
    Mira, J. A.
    Camacho, A.
    Neukam, K.
    Perez-Camacho, I.
    Caruz, A.
    Macias, J.
    Torre-Cisneros, J.
    Pineda, J. A.
    Rivero, A.
    INFECTION, 2013, 41 (01) : 21 - 26
  • [4] Insulin resistance and HCV virologic response to peg-interferons (Peg-IFN) with ribavirin (RBV) in HIV/HCV co-infected patients
    Donato, C.
    Cingolani, A.
    Pinnetti, C.
    De Luca, A.
    JOURNAL OF HEPATOLOGY, 2010, 52 (02) : 306 - 307
  • [5] Early virological response in HIV/HCV co-infected patients to IFN or Peg-IFN plus ribavirin assessed by HCV RNA measurement
    Payan, C.
    Pivert, A.
    Morand, P.
    Fafi-Kremer, S.
    Carrat, F.
    Pol, S.
    Cacoub, P.
    Perronne, C.
    Lunel, F.
    JOURNAL OF CLINICAL VIROLOGY, 2006, 36 : S134 - S134
  • [6] An open, multicenter, randomized trial comparing pegylated interferon alpha-2b (PEG-IFN) plus ribavirin (RBV) versus PEG-IFN for treatment of HIV/HCV co-infected patients.
    Cargnel, A
    Angeli, E
    Casella, A
    Gubertini, G
    Mainini, A
    Orlando, G
    Duca, P
    HEPATOLOGY, 2002, 36 (04) : 363A - 363A
  • [7] Camel Milk: Potential Utility as an Adjunctive Therapy to Peg-IFN/RBV in HCV-4 Infected Patients in Egypt
    Mohamed, Walid A.
    Schaalan, Mona F.
    El-Abhar, Hanan S.
    NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2015, 67 (08): : 1305 - 1313
  • [8] Treatment of HCV infected patients, including non-responders to PEG-IFN alfa2b/RBV, with PEG-IFN alfa2a/RBV: The Johns Hopkins experience
    Zeng, N
    Cohen, CK
    Schwartz, P
    Rai, R
    GASTROENTEROLOGY, 2004, 126 (04) : A722 - A722
  • [9] Efficacy of Rikkunshito on Anorexia in Chronic Hepatitis C Patients During PEG-IFN/RBV Therapy
    Arai, Makoto
    Matsumura, Tomoaki
    Maruoka, Daisuke
    Nakagawa, Tomoo
    Katsuno, Tatsuro
    Imazeki, Fumio
    Yokosuka, Osamu
    GASTROENTEROLOGY, 2013, 144 (05) : S568 - S568
  • [10] EFFECT OF HCV THERAPY ON IMMUNOLOGICAL HOMEOSTASIS IN HIV/HCV CO-INFECTED PATIENTS
    Airoldi, M.
    Nasta, P.
    Maggiolo, F.
    Di Gianbenedetto, S.
    Ladisa, N.
    Gatti, F.
    Suter, F.
    Fabbiani, M.
    Bandera, A.
    Gori, A.
    INFECTION, 2011, 39 : S78 - S78